Please find enclosed transcript of conference call with the Investors and Analysts held on May 4, 2026 at 3.00 p.m. IST.
GODREJAGRO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Godrej Agrovet delivered strong Q4 FY '26 results with consolidated revenues of INR 2,333 crores (9% YoY growth) and PBT of INR 87 crores (16.8% YoY growth). For full year FY '26, revenues crossed INR 10,000 crores to reach INR 10,233 crores with 17.2% PBT growth. Animal Nutrition saw 15% volume growth with cattle feed up 24%, while Oil Palm achieved record area expansion and highest ever oil extraction ratio. Crop Care was impacted by co-marketing channel inventory issues but management expects recovery from Q2 FY '27. Astec LifeSciences achieved EBITDA break-even driven by strong CDMO performance. Management guided for early double-digit revenue growth and mid-teens PBT growth in FY '27, with INR 400 crores capex (75-80% growth capex) and expected free cash flow surplus of INR 100-125 crores.
The company delivered margin expansion with PBT growing faster than revenues, and management's FY '27 guidance of mid-teens PBT growth signals continued margin improvement. Working capital reduction and strong cash generation support shareholder value. New product launches in Crop Care and continued momentum in Animal Nutrition and Oil Palm provide near-term growth catalysts.